Navigation Links
Cholesterol-lowering Drug Effective at Halting Early Atherosclerosis

An international study using ultrasound technology has found that the most potent cholesterol-lowering drug is also effective at halting// early changes in the blood vessels that can lead to atherosclerosis.

“Rosuvastatin arrested the progression of thickened carotid arteries compared to a placebo,” said John R.Crouse, M.D., lead researcher and a professor of endocrinology at Wake Forest University School of Medicine. “The findings show that the benefits of cholesterol management on arteries can be extended to low-risk patients.”

Results from the study were reported today at the annual meeting of the American College of Cardiology in New Orleans and will appear in the March 28 issue of the Journal of the American Medical Association. The research involved people with moderately elevated cholesterol levels who didn’t qualify for treatment under national guidelines.

Participants all had minimal thickening of their carotid arteries, which supply blood to the brain, and were considered at low risk for having a heart attack or dying from a heart-related event based on their age and other risk factors.

Over a two-year period, the therapy lowered low-density lipoprotein, or “bad” cholesterol, by 49 percent and increased high density lipoprotein, or “good” cholesterol, by 8 percent. Triglycerides were reduced by 16 percent and the progression of artery thickness was halted.

Rosuvastatin (sold under the trade name Crestor) is the newest member of a family of drugs known as statins that work to lower levels of cholesterol and other fats in the blood. Other statins have been tested – with similar results – in patients who’ve already had a heart attack or who had high cholesterol levels. This was the first study to evaluate Crestor in a group of people at low risk for heart attacks.

“Atherosclerosis is often advanced before symptoms appear and it hasn’t been clear whether treatment of low-risk individuals is beneficial,” said Crouse. “This study shows that aggressive cholesterol management arrests the progress of even small changes in the arteries.”

The study used ultrasound to assess whether Crestor was effective at halting progressive thickening of the carotid arteries. Vessel thickening is an early sign of atherosclerosis, the deposit of fatty material in blood vessels that can lead to heart attacks and strokes.

There were 984 study participants: 702 were randomly assigned to receive 40 mg of Crestor daily and 282 were randomly assigned to receive a placebo, or inactive tablet. Male participants were between 45 and 70 years old and females were between 55 and 70.

Crestor arrested the development of artery thickening overall and in all 12 sites of the carotid artery that were measured. Drug safety was assessed by vital signs, adverse events, laboratory tests and electrocardiograms. The frequency of adverse events was similar between the two groups and included muscle pain and gastrointestinal disorders.

“The drug was well tolerated during the two-year period and showed a similar safety profile to the placebo,” said Crouse.

The study included 61 primary care practices in the United States and Europe and was conducted between August 2002 and May 2006. Each participant was followed for two years and received an ultrasound exam at the beginning and end of the study and every six months during the study period.

Participants were considered at low risk of a heart attack or death from a heart-related-event based on a formula developed by the National Cholesterol Education Program from the long-running Framingham Heart Study, which takes such factors as age, sex, blood pressure and cholesterol levels into account. Low risk was considered a heart disease risk of less than 10 percent over a 10-year period.

Soure-Newswise
SRM
'"/>




Related medicine news :

1. Cholesterol-lowering therapy benefits older people also
2. Cholesterol-lowering drug Found To greatly Reduce the risk of stroke and heart attack
3. Growing Popularity of Cholesterol-lowering Drugs Raises Concern
4. New Way to "See" Genes, Evaluate Effectiveness of Gene Therapies Discovered
5. Inhaled Steroids Safe & Effective for Children with Asthma
6. ZD1839 Proves Effective - A Breakthrough in fighting Lung Cancer
7. Fluoride Found Effective in Osteoporosis
8. Aspirin and Warfarin Are Equally Effective for Stroke Prevention
9. Implantable Contact Lens Found Safe and Effective
10. Effective And Economical Agent For Anthrax
11. Stem Cell Transplants May Be Effective For MS Patients
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:6/26/2016)... ... 2016 , ... Quality metrics are proliferating in cancer care, and are derived ... eye of the beholder, according to experts who offered insights and commentary in the ... Care. For the full issue, click here . , For the American Society ...
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet supplements ... was developed to enhance the health of felines. The formula is all-natural and is ... herbs in the PawPaws Cat Kidney Support Supplement Soft Chews are Astragalus ...
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the American ... Annual Research Meeting June 26-28, 2016, at the Hynes Convention Center in Boston. ... including advance care planning, healthcare costs and patient and family engagement. , AIR ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture ... said Christina Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s package ... Final Cut Pro X . Simply select a ProHand generator and drag it ...
(Date:6/25/2016)... ... June 25, 2016 , ... ... recover from injury. Recently, he has implemented orthobiologic procedures as a method for ... is one of the first doctors to perform the treatment. Orthobiologics are substances ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... June 23, 2016 Roche (SIX: RO, ROG; ... for its Elecsys BRAHMS PCT (procalcitonin) assay as a ... septic shock. With this clearance, Roche is the first ... integrated solution for sepsis risk assessment and management. ... infection and PCT levels in blood can aid clinicians ...
(Date:6/23/2016)... Capricor Therapeutics, Inc. ... company focused on the discovery, development and commercialization ... in its ongoing randomized HOPE-Duchenne clinical trial (Halt ... its 24-patient target. Capricor expects the trial to ... 2016, and to report top line data from ...
(Date:6/23/2016)... -- Bracket , a leading clinical trial technology and ... platform, Bracket eCOA (SM) 6.0, at the 52 nd ... 2016 in Philadelphia , Pennsylvania.  A demonstration ... of its kind to fully integrate with RTSM, will be ... is a flexible platform for electronic clinical outcomes assessments that ...
Breaking Medicine Technology: